Mirum Pharmaceuticals (MIRM) Projected to Announce Quarterly Earnings on Tuesday

Mirum Pharmaceuticals (NASDAQ:MIRM) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Mirum Pharmaceuticals to announce earnings of ($0.4869) per share and revenue of $178.07 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same period in the previous year, the business posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. On average, analysts expect Mirum Pharmaceuticals to post ($1.32) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $83.27 on Tuesday. The firm has a fifty day moving average of $91.43 and a 200-day moving average of $98.41. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MIRM. Citizens Jmp reaffirmed a “market outperform” rating and issued a $137.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. Weiss Ratings lowered shares of Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday. TD Cowen increased their price target on Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, September 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $148.19.

Insider Transactions at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total transaction of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares in the company, valued at $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,440 shares of the company’s stock, valued at approximately $19,187,339.20. The trade was a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,499 shares of company stock valued at $9,797,834 over the last quarter. Corporate insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.